Articles tagged with Weight Loss
A new study found that patients who lost more weight with GLP-1 treatment had a lower risk of developing obesity-related conditions. In contrast, those who gained weight or only lost a small amount saw increased risks for osteoarthritis, chronic kidney disease, and heart failure.
A large real-world study comparing bariatric surgery to GLP-1 drugs found that surgery produced significantly greater weight loss and higher rates of obesity-related disease remission. After 12 months, patients who underwent surgery achieved more than 20% greater weight loss than those treated with GLP-1 therapy.
Regular physical activity is essential for mitigating the regain of lost weight after discontinuing GLP-1 medications. Exercise has complementary effects beyond energy balance, including improved insulin sensitivity and increased fat oxidation. Clinicians must develop individualized strategies to improve exercise adherence.
A new study from Rice University finds that using GLP-1 medications can lead to social judgment, even among those who have lost significant weight. Participants rated individuals who used GLP-1 more negatively than those who lost weight through diet and exercise or did not lose weight at all.
Researchers have discovered a new weight-loss mechanism that eliminates the need for GLP-1, reducing gastrointestinal side effects and increasing treatment tolerability. This breakthrough offers hope for patients who struggle with adverse reactions to existing obesity medications.
A new randomized clinical trial shows that a low-fat vegan diet reduces greenhouse gas emissions by nearly three times more than a Mediterranean diet. The study also found significant improvements in key cardiometabolic outcomes, with the majority of environmental gains driven by eliminating meat, dairy, and eggs.
A new study found comprehensive evidence that weight-loss GLP-1 receptor agonists like semaglutide reduce amyloid-beta and tau buildup in the brain. Consistent reductions were seen in animal and cell studies, with liraglutide showing the most positive effects.
A new procedure, duodenal mucosal resurfacing, has shown promising results in preventing weight regain after GLP-1 therapy discontinuation. The study found that patients who underwent the procedure maintained over 80% of their weight loss and regained less weight compared to those who received a sham procedure.
A new study has found that postmenopausal white women with higher genetic risk of obesity regained weight about two times faster than those with lower genetic risk. Despite this difference, Black women in the study regained weight at a similar rate, regardless of their genetic risk.
A new study from Aarhus University reveals that weight-loss drugs containing GLP-1 hormone may influence joint inflammation in arthritis patients. The study found that high doses of GLP-1 in medication could have a dual effect, both through weight loss and by increasing levels in the joints.
A lower semaglutide price could generate savings that offset the cost of treating an additional 550,000 to 3.6 million Medicare beneficiaries eligible for expanded obesity-indication coverage. This voluntary price agreement may lead to substantial savings for Medicare spending on semaglutide treatment.
A hormone called FGF21 reverses obesity in mice by signaling to the hindbrain, a region targeted by GLP-1 drugs. This finding provides insight into the naturally occurring hormone's benefits for weight loss and MASH treatment.
Researchers found that adults who followed routine eating patterns lost more weight than those with varied diets. Those who repeated many of the same foods lost an average of 5.9% of their body weight, compared to 4.3%. Greater calorie consistency was also linked to better results.
Researchers discovered an appetite-suppressing compound in python blood that promotes satiety without stomach problems. The compound, para-tyramine-O-sulfate, has potential for new weight loss treatments.
Researchers discovered a metabolite called pTOS in pythons that increases appetite suppression in obese mice, leading to significant weight loss. The study sheds light on the power of studying extremes in the animal kingdom and may lead to new weight-loss treatments.
Researchers developed a comprehensive genetic risk calculator for metabolic disease by integrating genetic data from hundreds of thousands of people worldwide. The polygenic risk score outperformed existing disease-prediction models and predicted downstream morbidity and clinical interventions, particularly in non-European populations.
A concerning rise in adolescent obesity has been found, with overall rates climbing to 15.9% in 2023. Obesity patterns also reveal a decline in weight-loss attempts, with females more likely to attempt weight loss but fewer adolescents reporting efforts in 2023.
A $3.4 million NIH grant will fund a semi-automated feedback system to support people tracking diet, exercise, and weight in weight-management programs. The system aims to provide personalized feedback to increase tracking and weight loss success.
Analysis of unintended side effect reports reveals that Wegovy carries the highest risk of 'eye stroke' and sudden sight loss among semaglutide drugs, with odds nearly 5 times higher than Ozempic. The risk is particularly pronounced in men, with a signal nearly 3 times higher than in women.
Patients who stop taking weight loss drugs like Ozempic and Wegovy experience rapid weight regain of up to 60% within a year, but sustain around 25% of lost weight. Researchers found that individuals may maintain healthier eating habits even after treatment ends.
Semaglutide and tirzepatide prescriptions increased dramatically between 2018 and 2025, while MBS use rates declined substantially starting in 2023. Recent shifts in MBS use may be more pronounced in certain patient subgroups, such as those seeking sleeve gastrectomy or with lower BMIs.
A large US study published in The BMJ found that GLP-1 receptor agonists used to treat type 2 diabetes and obesity may also help lower the risk of addiction to various substances. The study associated GLP-1 receptor agonists with reduced risks of adverse outcomes such as overdoses and drug-related emergency department visits and deaths...
A systematic review and meta-analysis found GLP-1 RAs produce significant weight loss across various subpopulations, including women who show improved outcomes compared to men. These findings have implications for clinical decision-making.
GLP-1 weight-loss drugs may prevent further tissue damage following a heart attack, significantly reducing the risk of further life-threatening complications. Researchers found that these drugs improve blood flow to the heart by activating potassium channels, relaxing constricted blood vessels and reducing heart damage risk.
A new study from the University of East Anglia found that the human brain continues to respond to tempting food cues even after eating enough. The research used EEG brain scans to monitor volunteers' brain activity as they played a reward-based learning game with food.
A phase 3 trial found that orforglipron, a novel GLP-1 receptor agonist pill, leads to greater blood sugar control and weight loss than current oral GLP-1 RA semaglutide in people with type 2 diabetes. Participants taking orforglipron had significantly greater reductions in body weight and blood sugar levels.
A new study finds that a novel GLP-1 receptor agonist, Exendin-4-Phe (Ex-Phe-1), preserves glycemic control while reducing malaise and vomiting behaviors in preclinical models. The compound uses biased agonism to selectively activate certain signaling pathways, achieving desired effects without triggering others.
A new study by Ben-Gurion University of the Negev researchers found that repeated attempts at weight loss confer significant and sustainable health benefits over time, particularly through reduced visceral fat. Even when participants regain all the weight lost in a previous diet, their cardiometabolic health may remain improved.
A new study finds salcaprozate sodium may have adverse biological effects on the gut and beyond, including shifts in potentially harmful gut bacteria and elevated inflammatory markers. The research highlights an important gap in understanding the long-term impact of repeated SNAC exposure.
A new Cochrane review suggests that intermittent fasting may not be an effective strategy for weight loss in overweight or obese adults. The study found no meaningful difference in weight loss between intermittent fasting and traditional dietary advice or doing nothing, highlighting the need for more research into this area.
A large-scale study found that patients taking tirzepatide had a significantly lower risk of developing new diabetic retinopathy or progressing to more severe stages. This suggests that the medication may not worsen eye health, offering relief for patients concerned about their vision.
A Rutgers Health study found that perceived effectiveness of semaglutide, such as noticeable weight loss or reduced food cravings, was the strongest predictor of satisfaction and intention to continue treatment. Although gastrointestinal issues like nausea and vomiting were common, they didn't significantly influence satisfaction score...
A cohort study reveals that infants from vegan households have similar growth patterns to those from omnivorous households, with a higher risk of early underweight at birth. As the findings suggest, further research is needed to examine the quality of vegan diets and the impact of nutritional counseling during pregnancy and infancy.
Researchers have quantified the role of obesity in common long-term conditions, showing that losing weight can prevent multiple diseases. Obesity was found to be the main shared cause between ten pairs of commonly occurring conditions, such as type 2 diabetes and osteoarthritis.
Researchers have found a nonlinear dose-response relationship between exercise and hepatic steatosis, indicating that a combination of aerobic and resistance exercises can produce clinically meaningful improvements. The study suggests that exercising above 130 MET-min/week can lead to significant reductions in hepatic steatosis.
A recent study from University Hospitals Cleveland Medical Center found that diagnostic abnormalities were no more likely to occur among adults with unintentional weight loss than among comparison patients. In most cases, the weight loss was not linked to a serious underlying condition, with only a .7% overall rate of cancer.
The W8Buddy study, a major real-world evaluation of digitally delivered specialist weight management pathways, is recruiting 450 participants from 4 Specialist Weight Management Services across England and Wales. The study aims to assess the long-term health benefits and economic impact of digital tools for obesity care.
Tufts researchers have developed a method to biosynthetically produce tagatose, a rare sugar with potential health benefits. Tagatose is 92% as sweet as sucrose and has about 60% fewer calories, making it an attractive alternative to conventional sugar substitutes.
A new study from University of Southern Denmark reveals that weight loss improves the health of fat tissue, reducing inflammation and immune cell activity. Moderate weight loss also promotes the formation of new and healthier fat cells, leading to improved insulin sensitivity.
Researchers at Vanderbilt Health found that both weight loss drugs and bariatric surgery induce a moderate loss of lean muscle and substantial reduction in fat, improving body composition in obese patients. This shift is associated with lower mortality risk from obesity-related diseases.
A new study found that more than one-in-four adults worldwide may be eligible for GLP-1 use, with women and older individuals among the most eligible. The research emphasizes the need to prioritize global access to these medications, particularly in low- and middle-income countries where obesity rates are highest.
Around 4.9 million British adults, nearly one in ten, have recently used or expressed interest in GLP-1 medications to support weight loss. The demand highlights substantial need for these medications, which help lower blood sugar, support weight loss, and reduce the risk of heart and kidney complications.
A new study found that 4.9 million adults in Great Britain have recently used a drug to support weight loss or were interested in using one in the near future. The usage far exceeds NHS England's initial goal of prescribing these drugs to 220,000 people over three years.
A systematic review finds that stopping weight loss drugs leads to rapid weight regain, reversing heart health markers in under two years. Average monthly weight gain is 0.4kg, with all cardiometabolic risk markers projected to return to pre-treatment levels within 1.4 years.
Experts warn that people taking weight loss drugs like semaglutide and tirzepatide may not receive sufficient nutritional guidance, leaving them at risk of nutrient deficiencies and muscle loss. The lack of robust evidence surrounding nutritional advice and support has significant implications for overall health and well-being.
A recent study found that adolescents with overweight or obesity who take glucagonlike peptide-1 receptor agonists (GLP-1RA) have a lower risk of acute asthma exacerbations. This association suggests a potential dual benefit, where GLP-1RA use could address both weight management and asthma prevention in this population.
Households taking GLP-1 medications reduce grocery spending by an average of 5.3%, while spending at fast-food restaurants and coffee shops also decrease. Ultra-processed foods see significant declines, whereas yogurt, fresh fruit, and meat snacks experience modest increases.
Researchers found that the healthy Nordic diet was more effective in reducing blood glucose levels and improving body weight, inflammation, and lipid profile compared to other diets. The study also showed that participants lost weight despite being allowed to eat as much as they wanted from recommended foods.
A new trial found that increasing or decreasing sugar intake in a person's diet has no effect on their preference for sweet foods. Researchers suggest that public health advice may need to focus on reducing sugar and energy-dense foods, rather than eliminating all sweet options.
A cohort study found an association between GLP-1 receptor agonist use and chronic cough. Researchers are now seeking to confirm the link's existence, strength, and mechanisms.
Researchers identified biological markers of inflammation, liver stress, and early damage to brain cells in young adults with obesity. Low blood levels of choline, essential for liver health and long-term brain function, were also found. These findings suggest that metabolic stress and inflammation may begin far earlier than expected.
A study found that pregnant women who discontinued GLP-1 medications before or early in their pregnancy experienced higher risks of weight gain, diabetes, hypertensive disorders, and preterm delivery. Those who stopped taking the medications gained an average of 7.2 pounds more weight during pregnancy.
A new analysis by the Physicians Committee for Responsible Medicine found that a vegan diet, including
The study found that GLP-1 receptor agonists are increasingly used for postpartum weight loss in overweight women without a documented diabetes diagnosis. The primary indication for use was weight reduction, suggesting a potential shift in treatment guidelines.
Researchers found that higher muscle mass combined with a lower visceral fat to muscle ratio tracks with a younger brain age. Building muscle and reducing visceral fat are actionable goals for improving brain health. The study used whole-body MRI and AI algorithms to quantify muscle volume, fat tissue, and brain age.
Combining improved diet quality with increased physical activity significantly reduces body fat, particularly visceral fat, associated with higher risks of diseases. The study found that simultaneous changes in both behaviors result in greater benefits than individual changes.
A review of 1.6 million women found that two-thirds experience excessive or inadequate weight gain during pregnancy, associated with complications such as preterm birth and large birth weight. The study supports the development of global healthy growth and weight gain standards to improve outcomes for mothers and babies worldwide.
A study comparing GLP-1 RAs found that all three drugs are relatively safe options for patients with type 2 diabetes, with minimal differences in kidney and cardiovascular risks. Liraglutide had a lower risk of all-cause mortality compared to dulaglutide.
Dr. Leanne Redman joins the Charles Perkins Centre to lead research on obesity, diet, and exercise, building on her extensive experience in women's health issues and translational research. With over 300 publications and numerous awards, she will expand the centre's impact on global health.
A study published in Pediatric Drugs found that children and adolescents with underweight are more likely to discontinue ADHD medication within a year. The researchers also found clear differences in dosage, gender, and age that can affect treatment outcomes.